Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
164.45
+1.04 (0.64%)
Aug 10, 2026, 3:12 PM EDT - Market open
Neurocrine Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,374 | 2,861 | 2,355 | 1,887 | 1,489 | 1,134 | |
Revenue Growth | 34.42% | 21.45% | 24.81% | 26.76% | 31.34% | 8.38% |
Cost of Revenue | 23.2 | 52.1 | 34 | 39.7 | 23.2 | 14.3 |
Gross Profit | 3,351 | 2,808 | 2,321 | 1,847 | 1,466 | 1,119 |
Selling, General & Admin | 1,352 | 1,156 | 1,007 | 887.6 | 752.7 | 583.3 |
Depreciation & Amortization Expenses | 16.4 | - | - | - | - | - |
Research & Development | 1,171 | 1,033 | 743.6 | 708.9 | 463.8 | 433.4 |
Other Operating Expenses | -28.6 | - | - | - | - | - |
Total Operating Expenses | 2,511 | 2,189 | 1,751 | 1,597 | 1,217 | 1,017 |
Operating Income | 794.8 | 619.1 | 570.5 | 250.9 | 249 | 102.5 |
Interest Income | 88.5 | 90.3 | 91 | 52.8 | 4.1 | 3.8 |
Interest Expense | -2.9 | - | -138.4 | - | -70 | -25.8 |
Other Non-Operating Income (Expense) | 1.2 | -4 | -37.1 | 28.4 | 30.8 | 20.9 |
Total Non-Operating Income (Expense) | 145.4 | 86.3 | -84.5 | 81.2 | -35.1 | -1.1 |
Pretax Income | 940.2 | 705.4 | 486 | 332.1 | 213.9 | 101.4 |
Provision for Income Taxes | 234.7 | 226.8 | 144.7 | 82.4 | 59.4 | 11.8 |
Net Income | 705.5 | 478.6 | 341.3 | 249.7 | 154.5 | 89.6 |
Net Income to Common | 705.5 | 478.6 | 341.3 | 249.7 | 154.5 | 89.6 |
Net Income Growth | 102.55% | 40.23% | 36.68% | 61.62% | 72.43% | -78.00% |
Shares Outstanding (Basic) | 100 | 100 | 100 | 98 | 96 | 95 |
Shares Outstanding (Diluted) | 103 | 103 | 104 | 101 | 99 | 98 |
Shares Change | 0.76% | -1.16% | 2.67% | 2.12% | 1.02% | 0.10% |
EPS (Basic) | 7.05 | 4.81 | 3.40 | 2.56 | 1.61 | 0.95 |
EPS (Diluted) | 6.82 | 4.67 | 3.29 | 2.47 | 1.56 | 0.92 |
EPS Growth | 101.77% | 41.95% | 33.20% | 58.33% | 69.56% | -77.89% |
Free Cash Flow | 870.4 | 748.7 | 557.2 | 361.6 | 322.9 | 233.1 |
Free Cash Flow Growth | 64.63% | 34.37% | 54.09% | 11.98% | 38.52% | 7.12% |
Free Cash Flow Per Share | 8.41 | 7.30 | 5.37 | 3.58 | 3.26 | 2.38 |
Gross Margin | 99.31% | 98.18% | 98.56% | 97.90% | 98.44% | 98.74% |
Operating Margin | 23.56% | 21.64% | 24.22% | 13.30% | 16.73% | 9.04% |
Profit Margin | 20.91% | 16.73% | 14.49% | 13.23% | 10.38% | 7.90% |
FCF Margin | 25.80% | 26.17% | 23.66% | 19.16% | 21.69% | 20.56% |
EBITDA | 842.1 | 649.2 | 597.6 | 272.2 | 264.6 | 113.4 |
EBITDA Margin | 24.96% | 22.70% | 25.37% | 14.42% | 17.77% | 10.00% |
EBIT | 794.8 | 619.1 | 570.5 | 250.9 | 249 | 102.5 |
EBIT Margin | 23.56% | 21.64% | 24.22% | 13.30% | 16.73% | 9.04% |
Effective Tax Rate | 24.96% | 32.15% | 29.77% | 24.81% | 27.77% | 11.64% |